Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 4 - You Need To See This

Streak Analysis Alert: Why Merck (MRK) Should Be on Your Radar This Week

Blue chips like MRK stock generally represent a 50/50 wager for any given week. However, certain conditions strongly tilt the odds toward one side of the spectrum.

Barchart

The sudden dismissal of public records staff at health agencies threatens government accountability

Mass layoffs at the Department of Health and Human Services are continuing as the agency makes good on its intention, announced on March 27, 2025, to shrink its workforce by 20,000 people. Among workers dismissed in early April were several teams responsible for fulfilling requests for access to previously unreleased…

The Conversation

What to Expect From Merck & Co.'s Next Quarterly Earnings Report

Merck & Co. will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

Merck Stock Just Reminded Us Why ‘Buy the Dip’ Is Not That Simple

This healthcare company is down more than 30% over the past 52 weeks but still may not be a good buy for value investors.

Barchart

Is Merck Stock Underperforming the S&P 500?

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Wall Street Predict 92% Upside for This Dividend Stock: Should You Buy It Now?

While there are short-term headwinds, Merck has a bright future ahead.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

Apple, Coca-Cola, IBM, Berkshire Hathaway: These companies are facing a DEI shareholder showdown in 2025

A fresh crop of shareholder proposals that would have once been unremarkable are now a closely watched battlefront in the war against corporate diversity and inclusion initiatives.

Fortune

Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows

Researchers, in a sense, manipulated each patient’s cancer in an attempt to prevent it from coming back.

Fortune

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Stock Market Today: Earnings Speak Louder Than Tariffs

Recent market reaction to Trump administration policy announcements has been "entirely normal."

Kiplinger

What Are Wall Street Analysts’ Target Price for Merck Stock?

Merck has considerably underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Roll Call

Kennedy to divest interest from HPV vaccine lawsuits - Roll Call

President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV vaccine manufacturer.

Top News

Woman Dies After Being Set On Fire In NYC Subway

Tragic death of Debrina Kawam in New York subway fire highlights safety concerns and the need for increased support services for vulnerable populations.

Fortune

Breast cancer drug Lynparza reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The Conversation

Vaccine misinformation distorts science – a biochemist explains how RFK Jr. and his lawyer’s claims threaten public health

Vaccinations provide significant protection for the public against infectious diseases and substantially reduce health care costs. Therefore, it is noteworthy that President-elect Donald Trump wants Robert F. Kennedy Jr., a leading critic of childhood vaccination, to be secretary of Health and Human Services.

Benzinga

Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg.

Barchart

How Is Merck's Stock Performance Compared to Other Pharmaceuticals Stocks?

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Benzinga

Merck & Co Unusual Options Activity For December 02

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Freedom of Information Act

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.